This cost-utility analysis reports on the effect of quality of life on the value of screening all new patients with colorectal cancer for Lynch Syndrome.
Kathryn A. Phillips, PhD
Advertisement
Articles by Kathryn A. Phillips, PhD
A study of major US private payers showed an important role and considerable shortcomings of external health technology assessment in coverage decisions on personalized medicine.
Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.
Advertisement
Latest Updated Articles
- Health Technology Assessment and Private Payers's Coverage of Personalized Medicine
Published: May 18th 2011 | Updated:
- Genomic Testing and Therapies for Breast Cancer in Clinical Practice
Published: May 15th 2011 | Updated:
- Willingness to Recommend a Health Plan: Who Is Dissatisfied and What Don't They Like?
Published: June 1st 2004 | Updated:
- Genetic Testing and Pharmacogenomics: Issues for Determining the Impact to Healthcare Delivery and Costs
Published: July 1st 2004 | Updated:
- Does Patient Cost Sharing Matter? Its Impact on Recommended Versus Controversial Cancer Screening Services
Published: February 1st 2004 | Updated:
- Influence of Patient Preferences on the Cost-Effectiveness of Screening for Lynch Syndrome
Published: May 9th 2012 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA to Remove Black Box Warnings From HRT, Debate Ensues
2
POLY-HF: Polypill Boosts Heart Function, Adherence in Heart Failure
3
Risk-Based Contracts May Not Cut Low-Value Care in Medicare Advantage
4
CAVIAR: Alirocumab Safely Lowers Cholesterol After Heart Transplant
5
